JP2025506408A5 - - Google Patents

Info

Publication number
JP2025506408A5
JP2025506408A5 JP2024546129A JP2024546129A JP2025506408A5 JP 2025506408 A5 JP2025506408 A5 JP 2025506408A5 JP 2024546129 A JP2024546129 A JP 2024546129A JP 2024546129 A JP2024546129 A JP 2024546129A JP 2025506408 A5 JP2025506408 A5 JP 2025506408A5
Authority
JP
Japan
Prior art keywords
alkyl
kras
cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/012299 external-priority patent/WO2023150284A2/en
Publication of JP2025506408A publication Critical patent/JP2025506408A/ja
Publication of JP2025506408A5 publication Critical patent/JP2025506408A5/ja
Pending legal-status Critical Current

Links

JP2024546129A 2022-02-03 2023-02-03 キナゾリンpan-KRas阻害剤 Pending JP2025506408A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202263306271P 2022-02-03 2022-02-03
US63/306,271 2022-02-03
US202263327625P 2022-04-05 2022-04-05
US63/327,625 2022-04-05
US202263352180P 2022-06-14 2022-06-14
US63/352,180 2022-06-14
US202263432243P 2022-12-13 2022-12-13
US63/432,243 2022-12-13
US202263434327P 2022-12-21 2022-12-21
US63/434,327 2022-12-21
US202363442648P 2023-02-01 2023-02-01
US63/442,648 2023-02-01
PCT/US2023/012299 WO2023150284A2 (en) 2022-02-03 2023-02-03 Quinazoline pan-kras inhibitors

Publications (2)

Publication Number Publication Date
JP2025506408A JP2025506408A (ja) 2025-03-11
JP2025506408A5 true JP2025506408A5 (cg-RX-API-DMAC7.html) 2026-02-04

Family

ID=87552808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546129A Pending JP2025506408A (ja) 2022-02-03 2023-02-03 キナゾリンpan-KRas阻害剤

Country Status (9)

Country Link
US (1) US20240025907A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472980A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506408A (cg-RX-API-DMAC7.html)
KR (1) KR20240145987A (cg-RX-API-DMAC7.html)
AU (1) AU2023216698A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239343A1 (cg-RX-API-DMAC7.html)
IL (1) IL314486A (cg-RX-API-DMAC7.html)
MX (1) MX2024009616A (cg-RX-API-DMAC7.html)
WO (1) WO2023150284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
WO2023020519A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. 1, 4-oxazepane derivatives and uses thereof
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
AU2023265688A1 (en) 2022-05-06 2024-10-17 PAQ Therapeutics Inc. Kras g12d proteolysis targeting chimeras
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
WO2024046370A1 (zh) * 2022-08-30 2024-03-07 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
WO2024051763A1 (zh) * 2022-09-08 2024-03-14 深圳福沃药业有限公司 用于治疗癌症的kras突变抑制剂的喹唑啉杂环类衍生物
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
TW202430182A (zh) * 2022-12-14 2024-08-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物,及其製備和治療用途
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024235225A1 (zh) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260087586A (ko) 2023-10-03 2026-06-11 피에이큐 테라퓨틱스 인코포레이티드 Kras 단백질분해 표적화 키메라
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025117828A1 (en) * 2023-12-01 2025-06-05 Theras, Inc. Compositions and methods for inhibition of ras
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025148868A1 (zh) * 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025214341A1 (zh) * 2024-04-08 2025-10-16 江苏恒瑞医药股份有限公司 二氢呋喃并[3,4-f]喹唑啉类化合物、其制备方法及其在医药上的应用
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245105A1 (en) * 2024-05-20 2025-11-27 Erasca, Inc. Kras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026002172A1 (zh) * 2024-06-26 2026-01-02 上海青润医药科技有限公司 Kras突变体抑制剂及其药物组合物、制备方法和应用
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
TW202610655A (zh) 2024-08-14 2026-03-16 美商必治妥美雅史谷比公司 Kras抑制劑
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026072560A1 (en) * 2024-09-30 2026-04-02 Ensem Therapeutics, Inc. Tetracyclic derivatives, compositions and methods thereof
WO2026080226A1 (en) * 2024-10-08 2026-04-16 Ensem Therapeutics, Inc. Tricyclic derivatives, compositions and methods thereof
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016245864C1 (en) * 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2022002102A1 (en) * 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
CA3191279A1 (en) * 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN113999226B (zh) * 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022135470A1 (zh) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022148422A1 (en) * 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
AU2022220678A1 (en) * 2021-02-09 2023-09-21 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
MX2023008463A (es) * 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
WO2022184178A1 (en) * 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022187527A1 (en) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline nitrile derivatives as kras inhibitors
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2022258974A1 (en) * 2021-06-10 2022-12-15 Redx Pharma Plc Quinazoline derivatives useful as ras inhibitiors
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof

Similar Documents

Publication Publication Date Title
IL314486A (en) Quinazoline compounds inhibit PAN-KRAS
JP2022509724A5 (cg-RX-API-DMAC7.html)
JP2022500385A5 (cg-RX-API-DMAC7.html)
JP2022500384A5 (cg-RX-API-DMAC7.html)
JP2022500381A5 (cg-RX-API-DMAC7.html)
JP2022500388A5 (cg-RX-API-DMAC7.html)
JP2024525993A5 (cg-RX-API-DMAC7.html)
JP2022535577A5 (cg-RX-API-DMAC7.html)
HRP20230377T1 (hr) Inhibitori mutacije kras g12c
RU2015125458A (ru) Производные пиримидин-2,4-диамина для лечения рака
JP2021519779A5 (cg-RX-API-DMAC7.html)
JP2022548255A5 (cg-RX-API-DMAC7.html)
JP2022500379A5 (cg-RX-API-DMAC7.html)
JP2016504289A5 (cg-RX-API-DMAC7.html)
JP2022530866A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
JP2019516718A5 (cg-RX-API-DMAC7.html)
JP2022544189A5 (cg-RX-API-DMAC7.html)
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2025000632A5 (cg-RX-API-DMAC7.html)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2007511504A5 (cg-RX-API-DMAC7.html)
BR112019012239A2 (pt) compostos de aminotiazol como inibidores de c-kit
HRP20210607T1 (hr) Izokinolin-3-il karboksamidi i njihova priprema i upotreba